ライフサイエンスコーパス: estrogen therapy

1 in the development of insensitivity to anti-estrogen therapy.

2 st cancer patients who are resistant to anti-estrogen therapy.

3 breast cancer regression resulting from anti-estrogen therapy.

4 breast cancer risk than is use of unopposed estrogen therapy.

5 BMD changes were independent of concomitant estrogen therapy.

6 er contribute to acquired resistance to anti-estrogen therapy.

7 Symptoms Scale subscale comparisons favored estrogen therapy.

8 ty was reduced to 46% (p < 0.01) in women on estrogen therapy.

9 gnaling, tumor growth and its effect on anti-estrogen therapy.

10 and benefits associated with postmenopausal estrogen therapy.

11 ether its effects exceed those expected with estrogen therapy.

12 partially explain the beneficial effects of estrogen therapy.

13 t may be related to adverse early effects of estrogen therapy.

14 e cardioprotective effects of postmenopausal estrogen therapy.

15 rough PRL/PAK1 may impart resistance to anti-estrogen therapies.

16 refore, there is a need for developing safer estrogen therapies.

17 tient-year in women with VTE associated with estrogen therapy (0 of 58) (P = 0.001 for the 3-group co

18 d, double-blind, placebo-controlled trial of estrogen therapy (1 mg of estradiol-17beta per day) in 6

19 t-year in women with VTE not associated with estrogen therapy (9 of 81), and 0.0% (CI, 0.0% to 3.0%)

20 Multivariable analysis identified diabetes, estrogen therapy (adjusted risk ratio 0.38, 95% confiden

21 Estrogen therapy alone did not reduce dementia or MCI in

22 investigations was to assess the effects of estrogen therapy alone or with progesterone on executive

23 ast cancer risk substantially more than does estrogen therapy alone.

24 the authors examined the association between estrogen therapy and bone mineral density in older Afric

25 We examined the relationship between estrogen therapy and coronary-artery calcium in the cont

26 elling evidence of cardiovascular benefit of estrogen therapy and estrogen and progestin therapy in o

27 ssessed thyroid function before they started estrogen therapy and every 6 weeks for 48 weeks thereaft

28 demonstrated during pregnancy and high dose estrogen therapy and is thought to be the primary mechan

29 ion compared to daily cranberry pills, daily estrogen therapy, and acupuncture.

30 tia are decreased in women who have received estrogen therapy, and betaE2 protects neurons in vitro a

31 New trials of lipid lowering, estrogen therapy, and hypertension control have added to

32 epression may benefit from short-term use of estrogen therapy, and its role for postmenopausal depres

33 Thus, estrogen therapy appears to have unique properties that

34 ovarian function remains intact, these anti-estrogen therapies are not as effective.

35 These beneficial effects of estrogen therapy are highly modified by apolipoprotein E

36 of 137 consecutive women receiving long-term estrogen therapy at the time of elective PTCA and during

37 The active regimens were conjugated equine estrogens therapy at 0.625 mg daily, alone or in combina

38 erated bone loss is seen after withdrawal of estrogen therapy but not after withdrawal of alendronate

39 l concentrations similar to that produced by estrogen therapy, but high-density lipoprotein cholester

40 oxine-binding globulin concentrations during estrogen therapy, but their serum free thyroxine concent

41 Estrogen therapy can promote cognitive function if initi

42 t in Th1/Th2 balance suggested that low dose estrogen therapy could bias the immune reaction toward a

43 Estrogen therapy did not change systolic pressure (128+/

44 Estrogen therapy did not reduce the risk of death alone

45 e antibiotics for 6 to 12 months and vaginal estrogen therapy effectively reduce symptomatic UTI epis

46 to reevaluate the circumstances under which estrogen therapy (ET) provides benefits against cerebral

47 women who were randomly assigned to receive estrogen therapy had a higher risk of fatal stroke (rela

48 ith never users, women taking unopposed oral estrogen therapy had increased risks of both serous tumo

49 The use of estrogen therapy has declined sharply after the Women's

50 These results demonstrate that estrogen therapy has no effect on infarction volume foll

51 However, anti-estrogen therapy has not been shown to be effective in e

52 orial trials of PFKFB3 antagonists with anti-estrogen therapies in ER(+) stage IV breast cancer patie

53 ctivity and continued responsiveness to anti-estrogen therapies in vitro.

54 he understanding of the role of estrogen and estrogen therapy in bladder health and pathogen defense

55 ussed with respect to therapeutic targets of estrogen therapy in brain.

56 igated the efficacy and safety of short-term estrogen therapy in decreasing noncognitive signs and sy

57 Investigation of high dose estrogen therapy in in vivo models of CNS hemorrhage, tr

58 Estrogen therapy in postmenopausal women has been associ

59 interest as potential alternatives to using estrogen therapy in treating menopausal symptoms.

60 Four trials of estrogen therapy in women with Alzheimer disease have be

61 Important new data on anti-estrogen therapy, including aromatase inhibitors and pur

62 t, in carriers of apolipoprotein E4 (ApoE4), estrogen therapy increased the risk of late-onset Alzhei

63 Estrogen therapy is known to prevent osteoporosis, but s

64 Moreover, topical vaginal estrogen therapy may be an effective means of reducing H

65 Antidepressant benefit associated with estrogen therapy may be independent of improvement in ph

66 with hypothyroidism treated with thyroxine, estrogen therapy may increase the need for thyroxine.

67 ese preliminary data suggest that short-term estrogen therapy may safely decrease the frequency and s

68 Relative to monkeys receiving either of the estrogen therapies, monkeys receiving placebo were impai

69 f Opportunity' hypothesis, which states that estrogen therapy must be administered within a limited p

70 eimer disease, but studies of the effects of estrogen therapy on Alzheimer disease have been inconsis

71 Effects of estrogen therapy on cognitive performance are due, at le

72 Beneficial effects of estrogen therapy on cognitive performance diminish with

73 rs examined the effect of a 4-week course of estrogen therapy on depression in perimenopausal and pos

74 r XIII genotypes and their interactions with estrogen therapy on risk of nonfatal myocardial infarcti

75 rs either does not initially respond to anti-estrogen therapy or develops resistance to such treatmen

76 n 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen

77 polymorphisms in determining the response to estrogen therapy or the risk of clinical cardiovascular

78 en receptor (ER(+)) and is treated with anti-estrogen therapies, particularly tamoxifen in premenopau

79 Epidemiological studies suggest that estrogen therapy protects against clinical expression of

80 D), whereas in individuals carrying ApoE2/3, estrogen therapy reduced the risk of AD.

81 and recent data indicate that postmenopausal estrogen therapy reduces the incidence of CHD by > 40%.

82 for the development and application of anti-estrogen therapies to treat cancer in premenopausal wome

83 The use of estrogen therapy to prevent cardiovascular disease in po

84 Later age at menopause, unopposed estrogen therapy use, and obesity were associated with i

85 Estrogen therapy was associated with a significantly gre

86 Unopposed estrogen therapy was associated with the Raynaud phenome

87 g prevalence, predictors, and treatment with estrogen therapy, was reviewed.

88 Given the known risks of estrogen therapy, we do not recommend estrogen for the p

89 evices, injectable bulking agents, and local estrogen therapy were inconsistent.

90 Estrogen therapy, which has been shown to increase NO bi

91 omly assigned to usual care (control group), estrogen therapy with micronized 17beta-estradiol alone

92 Clinical trial evidence indicates that estrogen therapy with or without progestins increases ve

93 Postmenopausal estrogen therapy, with or without concomitant progestin